BitcoinEthereumNews·
The post Elon Musk’s SpaceXAI to Release Grok 4.5 as GPT-5.6 and Fable 5 Intensify AI Race appeared on BitcoinEthereumNews.com. Elon Musk has revealed that SpaceXAI will release its latest AI model, Grok 4.5, to the public tomorrow following beta-phase testing. This comes as the AI race intensifies with the launch of Anthropic’s Fable 5 and the imminent launch of OpenAI’s GPT-5.6. SpaceXAI To Release Grok 4.5 To The Public Tomorrow In an X post, Elon Musk stated that SpaceXAI will make Grok 4.5 available to the public tomorrow, citing strong positive customer feedback from its beta test program. “It is an Opus-class model, but faster, more token-efficient, and lower cost,” he said about the AI model. This comes as the AI race between the top AI firms, including OpenAI and Anthropic, intensifies. Anthropic released Fable 5 and Mythos 5 last month, which it declared its most powerful AI models yet. Notably, the U.S. government had imposed an export control ban on these AI models, which w
Read full articleThe unveiling of Grok 4.5 signals intensified AI competition, potentially reshaping market dynamics and challenging existing leaders. The post SpaceXAI unveils Grok 4.5 AI model ahead of July 2026 public release appeared first on Crypto Briefing.
Elon Musk's tech company released the newest version of Grok on Wednesday, promising a cheaper, more efficient alternative to other powerful AI models.
GPT-Live's real-time interaction could revolutionize human-AI communication, enhancing user experience and setting new standards for voice AI. The post OpenAI launches GPT-Live to make ChatGPT Voice feel more human appeared first on Crypto Briefing.
The loan highlights Wall Street's growing interest in AI IPOs, potentially accelerating OpenAI's market entry and influencing AI sector dynamics. The post Bank of America extends $520M loan to OpenAI amid IPO speculation appeared first on Crypto Briefing.
Did we make the wrong bet on ‘Big A.I.’?
Anthropic's valuation surge highlights the escalating influence of AI firms in global markets, potentially reshaping tech investment landscapes. The post Anthropic reportedly valued at $965 billion following series H funding round appeared first on Crypto Briefing.
As enterprises struggle to manage their AI strategies, the US AI regulatory environment is sending a wide range of contradictory signals. OpenAI’s Wednesday announcement that it will now release GPT-5.6 Sol, along with Terra and Luna, on Thursday highlights the confusion. Initially, the US government said that it was asking OpenAI to limit access to its top models, including the three releasing Thursday, to a short list of companies. OpenAI seemingly agreed and held back their general availability. But on Wednesday, OpenAI reversed its position, with a statement on X saying simply: “GPT-5.6 Sol, along with Terra and Luna, will launch publicly this Thursday. We’re expanding preview access globally now.” No details were released about the extent of the expansion. Then the White House issued a statement, a copy of which it emailed to InfoWorld, saying that the US government “did not give OpenAI a ‘green light,’ approval or clearance to release its models. No such permission is required or
The post Boom Times For Autoimmune Disease Therapies appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more. To get it in your inbox, subscribe here. AbbVie’s Skyrizi is on track to become the world’s second-highest selling drug, according to pharma consultants Evaluate. The Associated Press AbbVie’s Skyrizi, an injectable drug for autoimmune diseases that include psoriasis and Crohn’s disease, is expected to surpass $33 billion in revenue in 2032, making it the world’s second-biggest selling drug, according to a recent report from pharma data and consulting firm Evaluate. That puts it smack between Eli Lilly’s GLP-1 blockbusters, Mounjaro (for diabetes) and Zepbound (for weight loss). “Only autoimmune disease drugs come close to rivaling Lilly’s anti-obesity blockbusters given their potential to treat dozens of conditions driven by s
